Chikungunya reported among US travelers returning from affected areas in the Americas.
Local transmission identified in Florida, Texas, Puerto Rico, and the US Virgin Islands.
Chikungunya is a mosquito-borne disease caused by the chikungunya virus (CHIKV), which can be found in many popular travel destinations.
It can lead to painful symptoms that last much longer than your vacation.
And it’s spreading.
from the Kimakonde language of East Africa, meaning “to become contorted”
Here’s what to know about chikungunya before your next trip:
like severe joint pain, high fever, and headache after being infected, which can last 1 to 2 weeks.
like severe joint pain and fatigue that last for months
or even years. These symptoms can get in the way of everyday activities like walking, going to work, and cooking.
In rare cases, it can even cause serious heart, brain, and eye complications.
Chikungunya reported among US travelers returning from affected areas in the Americas.
Local transmission identified in Florida, Texas, Puerto Rico, and the US Virgin Islands.
First local transmission of chikungunya in the Americas identified in Caribbean countries and territories—meaning that mosquitoes in the area are infected with the virus and spreading it to people.
According to the European Centre for Disease Prevention and Control (ECDC), Brazil has the highest chikungunya burden in the world.
Brazil:~243,000 cases
Paraguay:~123,000 cases
Due to climate change and other factors, Aedes mosquitoes continue to spread to new places, such as Italy (2007 and 2017) and France (2010, 2014, and 2017).
Burkina Faso: 473 cases
Senegal: 220 cases
Mali: 8 cases
Other countries with evidence of CHIKV transmission among humans (2019–2024):
Cameroon, Chad, Democratic Republic of the Congo, Djibouti, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Kenya, Malawi, Namibia, Nigeria, Republic of the Congo, and Sudan.
About 28 people per year tested positive for chikungunya virus in the US. All were returning from affected areas in Asia, Africa, or the Indian Ocean.
India: 93,465 cases
Thailand: 1277 cases
Malaysia: 177 cases
Pakistan: 18 cases
Other countries with evidence of CHIKV transmission among humans (2019–2024):
Cambodia, China, Laos, Maldives, Myanmar, Taiwan, and Vietnam.
Philippines: 2561 cases
Other countries with evidence of CHIKV transmission among humans (2019–2024):
Indonesia and Timor-Leste.
Over the past 50 years, chikungunya outbreaks have grown in size, reach, and severity.
In 2023, about 500,000 cases of chikungunya were recorded worldwide, including travel destinations in Latin America, Africa, and Asia.
Yes. Climate change has helped create suitable conditions for Aedes mosquitoes in Europe and the US, which is helping chikungunya spread to new areas.
Chikungunya is a viral disease spread by Aedes mosquitoes. They can live in many environments across the world, including cities, towns, and rural areas.
And they mostly bite during the day.
A person can become infected when a mosquito bites them after it has fed on someone who has the virus.
Unfortunately, there is no specific antiviral treatment for chikungunya, so care is limited to alleviating symptoms, staying hydrated, and resting.
That’s why it’s so crucial to prevent chikungunya.
Until recently, the only way to prevent chikungunya was to avoid Aedes mosquito bites. Doing that usually meant using bug spray, or wearing long sleeves and long pants all day.
But since Aedes mosquitoes often bite indoors—and are more active during the day than at night—even spending your whole trip inside might not offer consistent and reliable protection. And who wants to spend their whole vacation indoors?
VIMKUNYA is the first and only virus-like particle (VLP) vaccine for chikungunya virus. Since it's a VLP vaccine, that means it has no viral genetic material, and can't cause chikungunya virus infection.
See What makesVIMKUNYA is a vaccine for prevention of disease caused by chikungunya virus in people 12 years of age and older.
Additional clinical trials are required to confirm the clinical profile.
You should not get VIMKUNYA if you are allergic to any of the ingredients of the vaccine or if you have had an allergic reaction following a previous dose of VIMKUNYA.
People with a lowered immune system, including people receiving medications that affect the immune system, may have a diminished response to VIMKUNYA. Tell your healthcare provider about all medications you are taking.
Fainting may occur with administration of injected vaccines including VIMKUNYA.
The most common side effects were pain at the injection site, fatigue, headache, and muscle pain. These are not all the possible side effects.
Tell your healthcare provider if you are pregnant, planning to become pregnant, or are breastfeeding.
Tell your healthcare provider about any side effects that concern you. To report SUSPECTED ADVERSE REACTIONS, contact Bavarian Nordic at 1-844-4BAVARIAN or the US Department of Health and Human Services by visiting www.vaers.hhs.gov/reportevent.html or call 1-800-822-7967.
Please see full Prescribing Information here.
VIMKUNYA is a vaccine for prevention of disease caused by chikungunya virus in people 12 years of age and older.
Additional clinical trials are required to confirm the clinical profile.
You should not get VIMKUNYA if you are allergic to any of the ingredients of the vaccine or if you have had an allergic reaction following a previous dose of VIMKUNYA.
People with a lowered immune system, including people receiving medications that affect the immune system, may have a diminished response to VIMKUNYA. Tell your healthcare provider about all medications you are taking.
Fainting may occur with administration of injected vaccines including VIMKUNYA.
The most common side effects were pain at the injection site, fatigue, headache, and muscle pain. These are not all the possible side effects.
Tell your healthcare provider if you are pregnant, planning to become pregnant, or are breastfeeding.
Tell your healthcare provider about any side effects that concern you. To report SUSPECTED ADVERSE REACTIONS, contact Bavarian Nordic at 1-844-4BAVARIAN or the US Department of Health and Human Services by visiting www.vaers.hhs.gov/reportevent.html or call 1-800-822-7967.
Please see full Prescribing Information here.